Week of August 31, 2026
This Week's Two Biggest Moves Were Both Trial Failures
Alumis and Ultragenyx both fell sharply on late-stage clinical setbacks; Summit Therapeutics gained on data beating Keytruda head-to-head; ten real financings, macro sector performance, and more.